Our primary endpoints for MET outcomes in vivo were proliferation (Ki67 immunostaining) and apoptotic (TUNEL assay) status and changes in nuclear levels of tumor biomarker proteins ERα, PGR, KLF9, and PTEN. This evidence concerns the gene PTEN and neoplasm.